Patent · US Active

Multi-level specific targeting of cancer cells with IL-13

US8362207B2 · kind B2 · utility

17Cited by

19References

2Claims

0Family size

Assignee

Wake Forest University Health Sciences · US

Inventors

Waldemar Debinski · Winston-Salem, US
Hetal Pandya · Winston-Salem, US
Denise Gibo · Hershey, US

Key dates

Filing date	Apr 14, 2011
Grant date	Jan 29, 2013
Priority date	—
Expiry date	Apr 14, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/5437
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.